NCT01528800View on ClinicalTrials.gov

Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
End-stage Kidney Disease
Interventions
DRUG

Vitamin K1

10mg orally three times a week for 12 months

DRUG

Microcrystalline Methylcellulose

10mg orally three times a week for 12 months

Trial Locations (3)

K7L 2V7

Kingston Health Sciences Centre: Kingston General Hospital Site, Kingston

N6A 5W9

London Health Sciences Centre, London

K1H 8L6

The Ottawa Hospital, Ottawa

All Listed Sponsors
lead

Dr. Rachel Holden

OTHER

NCT01528800 - Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients | Biotech Hunter | Biotech Hunter